Skip to content

A randomized, double-blind, placebo-parallel controlled, multicenter clinical trial of efficacy and safety of Guhong injection in the treatment of unstable angina pectoris

A randomized, double-blind, placebo-parallel controlled, multicenter clinical trial of efficacy and safety of Guhong injection in the treatment of unstable angina pectoris

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045017
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unstable angina

Interventions

Sponsors

Beijing Chaoyang Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Volunteer to participate in the trial and sign the informed consent; 2. Age between 30 and 75 (including 30 and 75); 3. It meets the diagnostic criteria for unstable angina pectoris; 4. Patients with angina pectoris for at least 2 times within 10 days before enrollment; 5. Unstable angina pectoris, Braunwald grade I.

Exclusion criteria

Exclusion criteria: 1. Patients who need revascularization and/or are willing to undergo revascularization as determined by the investigator; 2. Patients with resting angina pectoris 48 hours before enrollment; 3. Chest pain caused by diseases other than coronary artery disease, such as severe neurosis, hyperthyroidism, cholecardiac syndrome, gastric and esophageal reflux, aortic dissection, etc.; 4. NYHA cardiac function grade III, IV; Left ventricular ejection fraction (LVEF) and the normal upper limit of serum creatinine (SCR) BBB> 7. People with bleeding tendency; 8. Previous history of hemorrhagic disease, or current concurrent hemorrhagic disease; 9. Other factors affecting the evaluation of total load of ischemic myocardium, such as cardiac hypertrophy, left bundle branch block, digitalis, electrolyte disturbance, etc.; 10. Those who had taken traditional Chinese medicine for coronary heart disease or angina pectoris within 1 week before inclusion and had the effects of promoting qi, promoting blood circulation and removing blood stasis; 11. People with allergic constitution or known allergy to the test drug; 12. A history of mental illness or drug or alcohol abuse; 13. Women who are pregnant or lactating, or have a family planning plan during the study period; 14. Participating in clinical trials of other drugs within the last 3 months; 15. The investigator considers it inappropriate to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
The number of angina attacks on day 10 changed from baseline;

Countries

China

Contacts

Public ContactXuecai Li
lixuecaiday@163.com+86 15834529066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026